Adjuvant Osimertinib and Atezolizumab has also been incorporated into the recent guidelines in EGFR mutant and ≥1% Programmed Cell Death Ligand-1 (PDL1) expressing tumours respectively.74–76. Here, EGFR is linked to neoplasm.